Spyre Therapeutics Net Income
| SYRE Stock | 36.51 0.56 1.56% |
As of the 18th of February 2026, Spyre Therapeutics has the Semi Deviation of 2.53, risk adjusted performance of 0.1644, and Coefficient Of Variation of 507.66. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spyre Therapeutics, as well as the relationship between them. Please validate Spyre Therapeutics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Spyre Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 36.51 per share. Given that Spyre Therapeutics has jensen alpha of 0.6615, we advise you to double-check Spyre Therapeutics's current market performance to make sure the company can sustain itself at a future point.
Spyre Therapeutics Total Revenue |
|
Gross Profit | Quarterly Earnings Growth (1.00) | Market Capitalization | Enterprise Value Revenue 2 K | Earnings Share (1.32) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -187.2 M | -177.9 M | |
| Net Loss | -187.2 M | -196.6 M | |
| Net Loss | (3.98) | (4.18) | |
| Net Income Per E B T | 1.15 | 1.10 |
Spyre | Net Income | Build AI portfolio with Spyre Stock |
Analyzing Spyre Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Spyre Therapeutics's current valuation and future prospects.
Latest Spyre Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Spyre Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Spyre Therapeutics financial statement analysis. It represents the amount of money remaining after all of Spyre Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Spyre Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spyre Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (208.02 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Spyre Net Income Regression Statistics
| Arithmetic Mean | (80,997,329) | |
| Coefficient Of Variation | (115.93) | |
| Mean Deviation | 69,495,052 | |
| Median | (44,348,000) | |
| Standard Deviation | 93,897,309 | |
| Sample Variance | 8816.7T | |
| Range | 328.4M | |
| R-Value | (0.80) | |
| Mean Square Error | 3456.9T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (14,787,232) | |
| Total Sum of Squares | 141067.3T |
Spyre Net Income History
Other Fundumenentals of Spyre Therapeutics
Spyre Therapeutics Net Income component correlations
Spyre Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Spyre Therapeutics is extremely important. It helps to project a fair market value of Spyre Stock properly, considering its historical fundamentals such as Net Income. Since Spyre Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spyre Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spyre Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Spyre diversify its offerings? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spyre Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Spyre Therapeutics requires distinguishing between market price and book value, where the latter reflects Spyre's accounting equity. The concept of intrinsic value - what Spyre Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spyre Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spyre Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spyre Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spyre Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spyre Therapeutics.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Spyre Therapeutics on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Spyre Therapeutics or generate 0.0% return on investment in Spyre Therapeutics over 90 days. Spyre Therapeutics is related to or competes with Pharvaris, Immunome, Wave Life, Intellia Therapeutics, Zymeworks Common, Maze Therapeutics, and Abcellera Biologics. Spyre Therapeutics is entity of United States More
Spyre Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spyre Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spyre Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.9 | |||
| Information Ratio | 0.1825 | |||
| Maximum Drawdown | 20.03 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 7.15 |
Spyre Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spyre Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spyre Therapeutics' standard deviation. In reality, there are many statistical measures that can use Spyre Therapeutics historical prices to predict the future Spyre Therapeutics' volatility.| Risk Adjusted Performance | 0.1644 | |||
| Jensen Alpha | 0.6615 | |||
| Total Risk Alpha | 0.5122 | |||
| Sortino Ratio | 0.2302 | |||
| Treynor Ratio | 0.6285 |
Spyre Therapeutics February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1644 | |||
| Market Risk Adjusted Performance | 0.6385 | |||
| Mean Deviation | 2.68 | |||
| Semi Deviation | 2.53 | |||
| Downside Deviation | 2.9 | |||
| Coefficient Of Variation | 507.66 | |||
| Standard Deviation | 3.66 | |||
| Variance | 13.36 | |||
| Information Ratio | 0.1825 | |||
| Jensen Alpha | 0.6615 | |||
| Total Risk Alpha | 0.5122 | |||
| Sortino Ratio | 0.2302 | |||
| Treynor Ratio | 0.6285 | |||
| Maximum Drawdown | 20.03 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 7.15 | |||
| Downside Variance | 8.4 | |||
| Semi Variance | 6.4 | |||
| Expected Short fall | (3.14) | |||
| Skewness | 0.9039 | |||
| Kurtosis | 1.98 |
Spyre Therapeutics Backtested Returns
Spyre Therapeutics appears to be very steady, given 3 months investment horizon. Spyre Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.21, which indicates the firm had a 0.21 % return per unit of risk over the last 3 months. By inspecting Spyre Therapeutics' technical indicators, you can evaluate if the expected return of 0.79% is justified by implied risk. Please review Spyre Therapeutics' Coefficient Of Variation of 507.66, semi deviation of 2.53, and Risk Adjusted Performance of 0.1644 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Spyre Therapeutics holds a performance score of 16. The entity has a beta of 1.13, which indicates a somewhat significant risk relative to the market. Spyre Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Spyre Therapeutics is expected to follow. Please check Spyre Therapeutics' expected short fall, as well as the relationship between the rate of daily change and period momentum indicator , to make a quick decision on whether Spyre Therapeutics' existing price patterns will revert.
Auto-correlation | 0.50 |
Modest predictability
Spyre Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Spyre Therapeutics time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Spyre Therapeutics price movement. The serial correlation of 0.5 indicates that about 50.0% of current Spyre Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.5 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 2.5 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Spyre Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Spyre Therapeutics reported net income of (208.02 Million). This is 160.95% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 136.43% higher than that of the company.
Spyre Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spyre Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spyre Therapeutics could also be used in its relative valuation, which is a method of valuing Spyre Therapeutics by comparing valuation metrics of similar companies.Spyre Therapeutics is currently under evaluation in net income category among its peers.
Spyre Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Spyre Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Spyre Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Spyre Fundamentals
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 2.69 B | ||||
| Shares Outstanding | 77.59 M | ||||
| Shares Owned By Insiders | 6.70 % | ||||
| Shares Owned By Institutions | 90.38 % | ||||
| Number Of Shares Shorted | 9.98 M | ||||
| Price To Book | 9.50 X | ||||
| Price To Sales | 650.22 X | ||||
| Revenue | 886 K | ||||
| Gross Profit | (177.5 M) | ||||
| EBITDA | (207.97 M) | ||||
| Net Income | (208.02 M) | ||||
| Total Debt | 84.56 M | ||||
| Book Value Per Share | 4.95 X | ||||
| Cash Flow From Operations | (157.41 M) | ||||
| Short Ratio | 16.56 X | ||||
| Earnings Per Share | (1.32) X | ||||
| Target Price | 56.71 | ||||
| Number Of Employees | 95 | ||||
| Beta | 3.16 | ||||
| Market Capitalization | 2.84 B | ||||
| Total Asset | 608.48 M | ||||
| Retained Earnings | (972.43 M) | ||||
| Working Capital | 554.41 M | ||||
| Net Asset | 608.48 M |
About Spyre Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Spyre Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Will Biotechnology sector continue expanding? Could Spyre diversify its offerings? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spyre Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Spyre Therapeutics requires distinguishing between market price and book value, where the latter reflects Spyre's accounting equity. The concept of intrinsic value - what Spyre Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spyre Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spyre Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.